文献速递关节外科创伤骨科骨质疏松与代谢性骨病

股骨颈骨折关节置换术后骨质疏松药物治疗预防假体周围骨折的成本效益:盈亏平衡分析

The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
PubMed 文献 · Osteoporos Int · 2024-04-15

该研究采用盈亏平衡分析评估股骨颈骨折关节置换术后使用骨质疏松药物预防假体周围骨折的经济可行性。结果显示口服双膦酸盐若将假体周围骨折率降低1.8%(即每56例中预防1例)则经济合理;3年药物成本需低于1500美元才具经济可行性。雌激素激素治疗、静脉双膦酸盐及新型药物需大幅降低成本方具经济可行性。

要点

  • 口服双膦酸盐预防假体周围骨折的盈亏平衡绝对风险降低为1.8%(每56例预防1例)。
  • 骨质疏松药物3年成本低于1500美元时,整体治疗预防假体周围骨折才具经济可行性。
  • 雌激素激素治疗需降低假体周围骨折率1.5%方具经济可行性。

核心结论

  • 口服双膦酸盐和雌激素激素治疗作为该人群假体周围骨折预防措施,若分别降低假体周围骨折率1.8%和1.5%,则具经济可行性。
  • 静脉双膦酸盐和新型药物在美国要作为假体周围骨折预防措施具经济可行性,其成本需大幅降低。

研究设计与样本

  • 研究采用盈亏平衡分析,使用骨质疏松药物3年平均成本、假体周围骨折护理成本及未接受骨质疏松治疗的股骨颈骨折髋关节置换术后患者假体周围骨折率进行评估。
  • 评估的药物包括口服双膦酸盐、雌激素激素治疗、静脉双膦酸盐、地舒单抗、特立帕肽和阿巴洛肽。

主要发现

  • 口服双膦酸盐治疗若预防56例假体周围骨折中的1例(绝对风险降低1.8%),则经济合理。
  • 基于当前成本和假体周围骨折发生率,整体治疗仅当这些药物3年成本低于1500美元时,对假体周围骨折预防才具经济可行性。
  • 雌激素激素治疗需降低假体周围骨折率1.5%方具经济可行性。

关键数值与推荐

  • 口服双膦酸盐的盈亏平衡假体周围骨折率为每56例预防1例,绝对风险降低1.8%。
  • 骨质疏松药物3年成本阈值低于1500美元。
  • 雌激素激素治疗的盈亏平衡假体周围骨折率降低为1.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Our study evaluated the economic viability of treatment in patients following arthroplasty and demonstrates that treatment with oral bisphosphonates can be cost-effective in preventing PPF. INTRODUCTION: Osteoporosis treatment following arthroplasty for femoral neck fracture (FNF) is associated with lower rates of periprosthetic fracture (PPF). Although cost-effective in reducing the rate of secondary fragility fracture, the economic viability of osteoporosis treatment in preventing PPF has not been evaluated. Therefore, the purpose of this study is to use a break-even analysis to determine whether and which current osteoporosis medications are cost-effective in preventing PPF following arthroplasty for FNFs. METHODS: Three-year average cost of osteoporosis medication (oral bisphosphonates, estrogen hormonal therapy, intravenous (IV) bisphosphonates, denosumab, teriparatide, and abaloparatide), costs of PPF care, and PPF rates in patients who underwent hip arthroplasty for FNFs without osteoporosis treatment were used to perform a break-even analysis. The absolute risk reduction (ARR) related to osteoporosis treatment and sensitivity analyses were used to evaluate the cost-effectiveness of this intervention and break-even PPF rates. RESULTS: Oral bisphosphonate therapy following arthroplasty for hip fractures would be economically justified if it prevents one out of 56 PPFs (ARR, 1.8%). Given the current cost and incidence of PPF, overall treatment can only be economically viable for PPF prophylaxis if the 3-year costs of these agents are less than $1500. CONCLUSION: The utilization of lower cost osteoporosis medications such as oral bisphosphonates and estrogen hormonal therapy as PPF prophylaxis in this patient population would be economically viable if they reduce the PPF rate by 1.8% and 1.5%, respectively. For IV bisphosphonates and newer agents to be economically viable as PPF prophylaxis in the USA, their costs need to be significantly reduced.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Agarwal AR, Kinnard MJ, Murdock C, et al. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis. Osteoporos Int. 2024. PMID: 38619605. doi:10.1007/s00198-024-07085-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。